DelveInsight, a leading healthcare market research and consulting firm, has released its latest report, “TIGIT Inhibitors Market Size, Target Population, Competitive Landscape, and Market Forecast – 2036.” The report provides a comprehensive understanding of the TIGIT inhibitors market, including target patient population, market size, market trends, competitive landscape, emerging therapies, market share, and forecasted opportunities across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.
Key Takeaways from the TIGIT Inhibitors Market
The TIGIT Inhibitors Market is anticipated to witness significant growth across the 7MM during the forecast period 2026–2036.
TIGIT inhibitors represent one of the most closely watched next-generation immune checkpoint inhibitor classes following the success of PD-1 and PD-L1 therapies.
The TIGIT inhibitors market size is projected to grow from approximately USD 10 million in 2029 to nearly USD 16 million by 2036, supported by anticipated product launches and expanding clinical adoption.
The target population for TIGIT inhibitors spans multiple oncology indications, including Non-Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma (RCC), Colorectal Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Melanoma, Peripheral T-Cell Lymphoma (PTCL), Anaplastic Large Cell Lymphoma (ALCL), and others.
Among lung cancer cases, NSCLC accounts for approximately 85% of all diagnoses, making it one of the largest commercial opportunities for TIGIT inhibitor development.
Currently, there are no approved TIGIT inhibitors, creating a significant first-mover opportunity for emerging therapies.
Leading companies developing TIGIT inhibitor therapies include Arcus Biosciences, Gilead Sciences, AstraZeneca, Compugen, Daiichi Sankyo, Roche, and others.
Promising TIGIT inhibitor therapies include Domvanalimab and Rilvegostomig, which are advancing through late-stage clinical development across multiple cancer indications.
Keen to know more about the market? Request our sample page for the TIGIT Inhibitors Market.
https://www.delveinsight.com/sample-request/tigit-inhibitors-market-forecast
Key Factors Driving the TIGIT Inhibitors Market
Growing Demand for Novel Immuno-Oncology Therapies
The continued success of immune checkpoint inhibitors has accelerated interest in next-generation immunotherapy targets. TIGIT has emerged as a highly attractive target due to its role in suppressing antitumor immune responses and its synergistic interaction with PD-1/PD-L1 pathways.
Expanding Addressable Cancer Patient Population
The increasing incidence of cancers such as NSCLC, RCC, colorectal cancer, melanoma, and HNSCC is creating a large addressable patient population for TIGIT inhibitors. Expanding treatment opportunities across multiple tumor types are expected to support long-term TIGIT inhibitor market growth.
Advancements in Combination Immunotherapy Strategies
Emerging clinical evidence suggests that TIGIT inhibitors may demonstrate enhanced efficacy when combined with PD-1/PD-L1 inhibitors, antibody-drug conjugates, and other immuno-oncology therapies. These combination approaches are expected to become a key market trend within the evolving cancer immunotherapy landscape.
TIGIT Inhibitors Competitive Landscape
The TIGIT inhibitors market remains highly competitive despite the absence of approved products. Several programs have been discontinued in recent years, including Belrestotug, Etigilimab, AGEN1777, and others, highlighting the challenges associated with TIGIT-targeted drug development.
However, late-stage assets such as Domvanalimab and Rilvegostomig continue to demonstrate commercial potential and are expected to play a pivotal role in shaping the future TIGIT inhibitors industry. These therapies leverage TIGIT blockade to restore CD8+ T-cell and NK-cell activity, enhancing antitumor immune responses and potentially improving outcomes when combined with established immunotherapies.
The anticipated approvals of these therapies may serve as a major inflection point for the TIGIT inhibitors market, restoring confidence in the mechanism and accelerating next-generation pipeline development.
Discover more about therapies set to grab major TIGIT Inhibitors market share @ TIGIT Inhibitors Treatment Landscape
Recent Developments in the TIGIT Inhibitors Market
In October 2025, Arcus Biosciences reported overall survival results from the Phase II EDGE-Gastric study evaluating Domvanalimab in combination with Zimberelimab and chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma.
In December 2025, Compugen and AstraZeneca amended their licensing agreement for Rilvegostomig, enabling Compugen to monetize a portion of future royalty streams and strengthen support for its immuno-oncology pipeline.
In September 2025, Genentech presented Phase III data from the SKYSCRAPER program evaluating Tiragolumab in hepatocellular carcinoma; however, the study did not meet its progression-free survival endpoint.
AstraZeneca continues to investigate Rilvegostomig in combination with DATROWAY and other therapies across multiple NSCLC and solid tumor settings.
What are TIGIT Inhibitors?
T-cell Immunoreceptor with Immunoglobulin and ITIM Domain (TIGIT) inhibitors are a novel class of immuno-oncology therapies designed to block the TIGIT immune checkpoint pathway. TIGIT is frequently co-expressed with PD-1 on exhausted T cells and natural killer cells, contributing to immune suppression within the tumor microenvironment. By inhibiting TIGIT signaling, these therapies restore immune cell activity, enhance antitumor responses, and may improve the efficacy of existing checkpoint inhibitors.
TIGIT Inhibitors Epidemiology Segmentation
The TIGIT inhibitors epidemiology section evaluates the addressable patient population across major oncology indications and includes:
Total Cases of Selected Indications for TIGIT Inhibitors
Total Eligible Patient Pool for TIGIT Inhibitors
Total Treated Cases in Selected Indications
Indication-Specific Target Population Analysis
Country-Specific Patient Pool Assessment
Scope of the TIGIT Inhibitors Market Report
Therapeutic Assessment: Emerging TIGIT inhibitor therapies
TIGIT Inhibitors Market Dynamics: Market drivers, barriers, opportunities, and future trends
Key Companies: Arcus Biosciences, Gilead Sciences, AstraZeneca, Compugen, Daiichi Sankyo, Roche, and others
Key Therapies: Domvanalimab, Rilvegostomig, Tiragolumab, and others
Competitive Intelligence Analysis: SWOT analysis, pipeline benchmarking, and market positioning
TIGIT Inhibitors Market Size, Market Share, Industry Trends, and Forecast
KOL Perspectives, Market Access, Pricing Trends, and Reimbursement Analysis
To know more about TIGIT inhibitor companies working in the treatment market, visit @ TIGIT Inhibitors Clinical Trials and Therapeutic AssessmentTable of Contents
TIGIT Inhibitors Market Report Introduction
Executive Summary of TIGIT Inhibitors
TIGIT Inhibitors Market Overview at a Glance
Clinical Landscape Analysis by Molecule Type, Phase, and Route of Administration
TIGIT Inhibitors Epidemiology and Target Patient Population
Indication-Specific Patient Pool Analysis
Treatment Guidelines and Current Immunotherapy Landscape
Emerging TIGIT Inhibitor Therapies
Domvanalimab: Clinical Development and Market Assessment
Rilvegostomig: Clinical Development and Market Assessment
TIGIT Inhibitors Market Outlook
Market Size Analysis by Country, Indication, and Therapy
United States TIGIT Inhibitors Market Analysis
EU4 and UK TIGIT Inhibitors Market Analysis
Japan TIGIT Inhibitors Market Analysis
Unmet Needs
SWOT Analysis
KOL Views
Market Access and Reimbursement
Appendix
Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical and biotechnology companies by providing comprehensive end-to-end solutions to improve business performance. DelveInsight offers actionable market intelligence, epidemiology forecasts, competitive landscape assessments, pipeline analysis, and strategic consulting services through its subscription-based healthcare intelligence platform, PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kirti SharmaEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
